Humana vs Andson Biotech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Humana (NYSE: HUM) with $115.8B revenue in 2024 (+12.7% YoY); 5.7M Medicare Advantage members; CenterWell Senior Primary Care expanding nationwide; #3 US health insurer combining managed care with a rapidly growing healthcare delivery arm.
About
Humana is one of the largest health insurance and healthcare services companies in the United States, founded in 1961 and headquartered in Louisville, Kentucky. Originally a nursing home operator, Humana pivoted to managed care in the 1980s and has since become a dominant force in Medicare Advantage — the government-funded private insurance alternative for Americans over 65. The company's mission centers on helping people achieve lifelong well-being by making healthcare simpler, more accessible, and more proactive.\n\nHumana's core businesses include Medicare Advantage plans, Medicaid managed care, military health services through its TRICARE contract, and a rapidly expanding healthcare delivery arm through CenterWell — which operates senior-focused primary care clinics, home health services, and specialty pharmacy. With 5.7 million Medicare Advantage members, Humana is the #3 US health insurer by total enrollment and the #2 Medicare Advantage carrier in the country. The CenterWell strategy represents a long-term shift from pure insurance toward vertically integrated care delivery.\n\nHumana posted $115.8 billion in revenue for 2024, a 12.7% increase year-over-year, driven by sustained demand growth as the US population ages into Medicare eligibility. The company faces margin pressure from elevated medical costs in Medicare Advantage — an industry-wide challenge through 2024–2025 — but its vertically integrated care model and concentrated scale in the senior market give it structural competitive advantages that differentiate it from pure-play insurance carriers.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
About
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.